<http://schema.org/description>
"The price for Gilead&amp;#39;s new hepatitis C cure seems exorbitant to some, and now pharmacy benefit managers are starting to push back along with the protestors. Here&amp;#39;s why Gilead&amp;#39;s pricing will still probably hold."^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2014/01/28/how-gilead-sciences-inc-could-push-back-on-sovaldi.aspx>